Anti-CBR1 Antibody (2C9-B12-C4)
Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF |
---|---|
Primary Accession | P16152 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | Mouse IgG1 |
Clone Names | 2C9-B12-C4 |
Calculated MW | 30375 Da |
Gene ID | 873 |
---|---|
Application & Usage | WB: HeLa, A431 and MDA-MB-468 cell lysates; IF: HeLa cells |
Other Names | Carbonyl reductase [NADPH] 1, 15-hydroxyprostaglandin dehydrogenase [NADP(+)], NADPH-dependent carbonyl reductase 1, Prostaglandin 9-ketoreductase, Prostaglandin-E(2) 9-reductase, Short chain dehydrogenase/reductase family 21C member 1 |
Target/Specificity | CBR1 |
Antibody Form | Liquid |
Appearance | Colorless liquid |
Formulation | In PBS (pH 7.4) containing with 0.2% sodium azide, 50% glycerol |
Handling | The antibody solution should be gently mixed before use. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | Anti-CBR1 Antibody (2C9-B12-C4) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CBR1 (HGNC:1548) |
---|---|
Synonyms | CBR, CRN, SDR21C1 |
Function | NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:18449627, PubMed:15799708, PubMed:17912391, PubMed:7005231, PubMed:1921984, PubMed:17344335, PubMed:18826943). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione- conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:18826943, PubMed:17344335). In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue (PubMed:28878267). |
Cellular Location | Cytoplasm. |
Tissue Location | Expressed in kidney (at protein level). |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alpha. Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.